California’s Division of Workers’ Compensation (DWC) issued an update increasing reimbursements for the Physician and Non-Physician Practitioner portion of the Official Medical Fee Schedule (OMFS) for workers’ compensation, effective for dates of service on or after April 1, 2024.
STARTING TODAY: CA Physician Fee Schedule reimbursement increases by 1.66%. The higher reimbursements are due to an increase in the Conversion Factor used to calculate OMFS physician reimbursement rates.
daisyBill providers do not need to take any action; we have uploaded the new reimbursements to our billing software effective for all dates of service on or after April 1. daisyBill automatically reports if any payments are below the most current effective fee schedule rates, and prompts providers to file (instant) Second Review appeals to dispute incorrect reimbursements.
Non-daisyBill providers are advised to adjust their systems and begin billing at the new rates for dates of services starting April 1.
All California providers should know that claims administrators may erroneously reimburse at the previous rates, requiring Second Review appeals.
The DWC announced the update in a recent Newsline, and posted the order adopting the updated reimbursements on its OMFS website. The update aligns the OMFS to relevant 2024 changes in the Medicare payment system, as required by California Labor Code Section 5307.1.
The updated Physician Fee Schedule contains three substantive changes:
Per the Centers for Medicare and Medicaid Services (CMS), the Conversion Factor used to determine Medicare reimbursements has gone up (emphases ours):
Due to the extraordinary practice expenses of treating injured workers, the DWC generally adjusts the Physician Fee Schedule to pay substantially more than Medicare for the same services. Effective for dates of service on or after April 1, the Conversion Factor for physician reimbursements increases from $47.72 to $48.51.
The increase in the Conversion Factor effectively maintains the California workers’ comp reimbursement rates relative to Medicare, with the Physician Fee Schedule reimbursing at 145.72% of Medicare rates.
With the OMFS Conversion Factor increase, the DWC acknowledges that treating injured workers requires about 45.72% more work than treating a Medicare patient — though California still allows PPOs to drastically reduce reimbursement rates to well below OMFS (and sometimes even below Medicare) rates.
The table below provides a comparison of Medicare and OMFS Conversion Factors in 2024 and the resulting difference in reimbursement rates between Medicare and the CA Physician Fee Schedule:
Medicare Effective Date |
Medicare End Date |
Medicare Conversion Factor (CF) |
YOY Change Medicare CF |
Physician Fee Schedule Effective Date |
Physician Fee Schedule End Date |
Physician Fee ScheduleConversion Factor (CF) |
YOY Change Physician Fee Schedule CF |
Physician Fee Schedule % of Medicare |
1/1/2024 |
3/8/2024 |
32.7442 |
-3.37% |
2/15/2024 |
3/31/2024 |
47.7200 |
1.08% |
145.74% |
3/9/2024 |
12/31/2024 |
33.29 |
1.67% |
47.7200 |
143.35% |
|||
3/9/2024* |
12/31/2024 |
33.29 |
4/1/2024 |
48.5100 |
1.66% |
145.72% |
*Note: the Medicare Conversion Factor increase was effective for DOS on/after 3/9/2024; the OMFS Physician Fee Schedule Conversion Factor increase is effective for DOS on/after 4/1/2024.
Listed below are the 36 new Healthcare Common Procedure Coding System (HCPCS) codes adopted by the DWC (and CMS) for Q2 2024, and the single HCPCS code the DWC deleted from the Physician Fee Schedule.
Note that when Medicare fails to assign an HCPCS code a Relative Value Unit (RVU), the reimbursement is calculated “By Report” (BR).
California Code of Regulations Section 9789.12.4 provides guidelines to determine appropriate reimbursement amounts for BR codes.
HCPCS |
Description |
Reimbursement Calculation |
J0578 |
Inj,brixadi, more than 7 day |
By Report |
J0209 |
Inj, sod thiosulfate (hope) |
By Report |
J2919 |
Inj, methylpred sod succ 5mg |
By Report |
Q4308 |
Sanopellis, per sq cm |
By Report |
J0650 |
Inj, levothyroxine nos 10mcg |
By Report |
J7354 |
Cantharidin top, applicator |
By Report |
J9248 |
Inj melphalan (delcath) 1 mg |
By Report |
J9249 |
Inj, melphalan (apotex) 1 mg |
By Report |
Q4307 |
American amnion, per sq cm |
By Report |
J1434 |
Inj, focinvez, 1mg |
By Report |
J9075 |
Inj, cyclophosphamide, nos |
By Report |
Q5133 |
Inj, tofidence, 1 mg |
By Report |
J0177 |
Inj, aflibercept hd, 1 mg |
By Report |
J0589 |
Inj daxibotulinumtoxina-lanm |
By Report |
J2782 |
Inj avacincapted pegol 0.1mg |
By Report |
J1323 |
Inj, elranatamab-bcmm, 1 mg |
By Report |
G0138 |
Iv cipaglucosidase alfa-atga |
By Report |
J1203 |
Inj, cipaglucosidase, 5 mg |
By Report |
J2801 |
Inj, rykindo, 0.5 mg |
By Report |
J9074 |
Inj, cyclophosphamd, sandoz |
By Report |
J1202 |
Miglustat oral 65 mg |
By Report |
J7165 |
Inj, human-lans, per i.u |
By Report |
J1010 |
Inj, methylpred acetate 1 mg |
By Report |
J3424 |
Inj, hydroxocobalamin iv 10g |
By Report |
Q4306 |
Americ amnion ac per sq cm |
By Report |
J9073 |
Inj cyclophosphamd (ingenus) |
By Report |
J0651 |
Inj, levothyroxine, freskabi |
By Report |
J9376 |
Inj pozelimab-bbfg, 1 mg |
By Report |
J3055 |
Inj talquetamab-tgvs 0.25 mg |
By Report |
Q4310 |
Procenta, per 100 mg |
By Report |
J2277 |
Inj, motixafortide, 0.25 mg |
By Report |
Q5134 |
Inj, tyruko, 1 mg |
By Report |
Q4309 |
Via matrix, per sq cm |
By Report |
J0577 |
Inj, brixadi, 7 days or less |
By Report |
Q4305 |
Amer am ac tri-lay per sq cm |
By Report |
J0652 |
Inj, levothyroxine, hikma |
By Report |
The update to the Physician Fee Schedule deletes one procedure code, as listed below.
HCPCS |
Description |
J1246 |
N/A |
Again, bills submitted via daisyBill will automatically reflect the most current, accurate reimbursement rates. If you have any questions regarding this fee schedule update, use the chat function at the bottom right of this screen or email our experts at info@daisybill.com.
DaisyBill provides content as an insightful service to its readers and clients. It does not offer legal advice and cannot guarantee the accuracy or suitability of its content for a particular purpose.